Texture_linecircles.png
OUR SCIENCE
Video_still.jpg
backgroundarrow.png

We develop off-the-shelf immune cell therapies to target cancer cells and infectious diseases without the need for donor-recipient matching

OUR LEADING 
CELL THERAPY PROGRAMS

Unmodified Immune Effector Cells

Our Unmodified DVX201 NK Cell Product is designed to boost natural immunity and reduce viral load in treating COVID-19, other infectious diseases, and heme malignancies

Cell_NK.png

Modified Immune Effector Cells

Our CAR-NK and Engineered Myeloid Cell Programs are off-the-shelf allogeneic cellular  immunotherapies designed for use separately or in combination to treat hematological malignancies and solid tumors

Cell_Myeloid_Engineered.png

Stem and
Progenitor Cells

Dilanubicel, our lead candidate, focuses on extending remissions and/or expanding access to curative treatments for Acute Myeloid Leukemia (AML)

Cell_Progenitor.png
diagram_science3.png

BENEFITS OF OUR SCIENCE

Deverra’s Notch
Ligand Platform

• allows for the scalable generation of lineage-specific cell products: hematopoietic stem and progenitor (dilanubical), lymphoid cells (NK cells), myeloid cells (macrophages)

• uses cord blood CD34+ cells as starting material, with high capacity for regeneration and minimal risk of having acquired genetic mutations, tumorigenicity, or transmissible diseases

• provides ultimate flexibility in methods/timing for cell engineering during stem cell expansion or immune cell differentiation phases

Deverra’s Allogeneic Cell
Therapy Products

• are intended for use as off-the-shelf, non-engrafting universal cell therapies, with no HLA matching required, allowing for immediate patient access

• are based on more than 20 years of bench-to-bedside research and have an extensive safety record with >300 infusions to date

• can be used as either stand-alone or combination cell therapies

Texture_shootinglines.png

MANUFACTURING / SUPPLY CHAIN

  • Onsite storage conditions for immediate on-demand use

  • Bedside thaw and direct infusion

  • Delivery successfully executed to 36 study sites in USA, Korea, Australia

  • Cells harvested into fixed dose aliquots ready for infusion

  • Products fully qualified prior to release for infusion

  • Hundreds of doses generated per manufacturing run at scale

  • Cryopreserved cells for off-the-shelf use and shipping to clinical sites

  • Donor-qualified cord blood units from FDA licensed public cord blood banks

 

  • No donor genotyping or matching required

  • CD34+ cell isolation from pooled cord blood units overcomes donor-to-donor variability and is scalable for desired output

  • Notch mediated CD34+ cell expansion and directed differentiation to create distinct immune cell products

  • Extensive flexibility for cell engineering from stem cell expansion to differentiation

 

  • Multiple successful tech transfers

  • Regulator reviewed comparability protocols

diagram_manufactoring.png